Table 1.
Baseline characteristics of PsA patients.
| Total Cohort | PLG | RWG | ||
|---|---|---|---|---|
| n | 293 | 54 | 239 | |
| M:F | 126:167 | 21:33 | 105:134 | |
| Age, median (IQR), yrs | 60 (53–68) | 61 (52.5–67) | 60 (53–68) | |
| Smokers: yes/former/no * | 46:37:208 | 10:9:35 | 36:28:173 | |
| BMI, median (IQR), kg/m2 ** | 26 (23.7–29.4) | 25.9 (23.5–29.7) | 26.1 (23.8–29.3) | |
| PsA duration, median (IQR), months | 49 (17–98.25) | 23 (13–65) | 53 (20–101.5) | |
| PsA phenotype | Oligo-articular Poli-articular Enthesitic Dactylitis Axial |
164 129 144 101 36 |
26 28 23 18 7 |
138 101 121 83 29 |
| SJC, median (IQR) | 3 (2–4) | 4 (3–6) | 2 (2–4) | |
| TJC, median (IQR) | 6 (3–10) | 6 (4–12) | 6 (3–9) | |
| LEI, median (IQR) | 0 (0–2) | 0 (0–2) | 0 (0–2) | |
| Dactylitis, median (IQR), fingers | 0 (0–1) | 0 (0–0) | 0 (0–1) | |
| CRP, median (IQR), mg/dL | 2.0 (0.7–4.6) | 2.5 (1.0–5.2) | 1.9 (0.6–4.2) | |
| DAPSA, median (IQR) | 24.4 (19.4–32) | 28.7 (23.1–36.9) | 24 (18.5–31) | |
| Prior csDMARDs use, n | MTX LFN SSZ CYA |
188 50 76 27 |
32 8 14 1 |
156 42 62 26 |
| Prior bDMARDs use, n | TNFi IL17i IL12/IL23i Abatacept |
81 21 20 2 |
0 0 0 0 |
81 21 20 2 |
| Concomitant csDMARDs, n | 58 | 10 | 48 | |
| Concomitant relevant disease, n | Cancer HCV/HBV Latent TB Other infections |
89 16 17 20 |
0 0 0 3 |
89 16 17 17 |
Data missing in 2 (*) and 20 (**) patients. BMI body mass index, PLG PALACE-like group, RWG real-world group, IQR interquartile range, SJC swollen joint count, TJC tender joint count, LEI Leeds enthesitis index, CRP C-reactive protein, DAPSA Disease Activity index for Psoriatic Arthritis.